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Increasing Age and Carcinoma Not Otherwise Specified
A 20-Year Population Study of 40,118 Lung Cancer Patients
Camilla Maria T. Sagerup, MD,*† Milada Småstuen, cand scient,‡ Tom B. Johannesen, MD, PhD,‡
Åslaug Helland, MD, PhD,*†§ and Odd Terje Brustugun, MD, PhD*†§
Background and Aim: New treatment regimens require a differ-
entiation between histological subsets of non-small cell lung cancer.
We aimed to assess how the incidence and prognosis of carcinoma
not otherwise specified (NOS) coincide with an aging patient pop-
ulation, disease stage, and diagnostic methods used.
Methods: Complete national data on 40,118 cases (including 6,597
diagnosed with carcinoma NOS) from the Cancer Registry of
Norway (1988–2007) are presented.
Results: The proportion of elderly patients (70 years and older) have
increased to over half of all patients diagnosed, a trend also evident
among carcinoma NOS patients. The proportion of carcinomas NOS
reported to the cancer registry in this 20-year period has increased
from 12% in 1988 to 19% in 2007. Crude 5-year relative survival in
carcinoma NOS was lowest of all non-small cell lung cancer entities
throughout the 20-year period; however, patients diagnosed with
carcinoma NOS in the period 2003 to 2007 had about 24% lower
risk of dying within 5 years after diagnosis compared with patients
diagnosed between 1988 and 1992, adjusted for covariates. Most
lung cancers are diagnosed by biopsy of the primary lesion; although
the proportion is lower among carcinomas NOS than other histo-
logical entities. By the last 5-year period studied, carcinoma NOS
was the histological entity most commonly diagnosed by cytology
(38%).
Conclusion: The proportion of carcinomas NOS has increased to
19% of all lung cancer cases. This histological entity is associated
with older age and poor survival.
Key Words: Lung carcinoma, Carcinoma NOS, Age, Survival,
Incidence.
(J Thorac Oncol. 2012;7: 57–63)
Lung cancer is not only the most common cancer in theworld; it is increasingly a cancer of the elderly. Median
age at time of diagnosis is now approaching 70 years,1 and
patients aged 70 years and older currently account for close to
50% of all lung cancers.1–3 Nevertheless, our knowledge
about the optimal treatment for lung cancer in older patients
is limited as elderly patients are often underrepresented or
excluded from clinical trials.4,5
Furthermore, new diagnostic challenges have arisen
with the emergence of clinical trials that brought on the
advent of histology-specific treatment regimens.6,7 Until re-
cently, treatment options did not vary between histological
entities of non-small cell lung cancer (NSCLC), hence treat-
ment after a diagnosis of NSCLC carcinoma not otherwise
specified (NOS) did not differ from that of other non-small
cell histologies.
Current changes in treatment practices, however, high-
light the importance of monitoring epidemiological data to
assess how patient demographics coincide with new diagnos-
tic demands. With access to complete, national cancer regis-
try data encompassing 40,000 patients within the 20-year
period 1988 to 2007, we aimed to assess how an aging patient
population, disease stage, and diagnostic methods play a role
in the incidence and prognosis of carcinoma NOS, a diag-
nostic entity given over 6,500 patients in this period.
MATRIALS AND METHODS
Population Demographics
Norway has a universal, public health service financed
by taxation and a national insurance scheme equally acces-
sible to all residents, independent of geography or social
status.
Data Collection
Since 1952, it has been mandatory by law to report all
malignant neoplasms to the Cancer Registry of Norway
(CRN). In addition, copies of cytology, biopsy, and autopsy
reports are submitted from pathology laboratories and death
certificate reports from the Cause of Death Register run by
the National Statistics Bureau, Statistics Norway. Since 1993,
all hospitals have filed discharge summaries electronically to
the registry. The system of reporting to CRN was evaluated in
2009, and overall completeness of reporting was estimated at
98.8%.8
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Data Analysis
We used the CRN database December 2008 submission
to analyze patient demographics, including histology, age,
stage, and diagnostic method used. When both biopsy and
cytology is performed in primary diagnostics, biopsy is reg-
istered as primary method. Age-specific incidence rates (IRs)
were estimated (per 100,000) with number of cases in each
age group in the denominator and the number of person-years
of that age group in the numerator.
We calculated 5-year male and female relative survival
(RS) stratified by age, stage, and histological type for indi-
viduals diagnosed through successive 5-year calendar peri-
ods. Not all deaths among cancer patients are because of the
primary cancer under study, and deaths resulting from other
causes could lead to lower survival estimates. In addition, the
cause of death is not always known and reliable. RS provides
an estimate of net survival and thus circumvents the above
problem. It is defined as the observed survival proportion in
a patient group divided by the expected survival of a com-
parable group in the general population with respect to age,
sex, and calendar year of investigation.9
The effect of selected covariates (gender, age, stage,
and diagnostic period) on survival was modeled using Cox
proportional hazards regression. The assumption of propor-
tional hazards was checked by means of visual inspection of
log minus log plots. All statistical tests were two sided and p
values 0.05 were considered statistically significant. All
statistical analyses were performed using STATA version 11
and SPSS version 18.
Diagnosis and Staging
We included only cases of carcinomas NOS with his-
topathological reports that had a final conclusion from the
pathologist of carcinoma NOS. Cases where the diagnostic
method was unknown or listed as noninvasive (radiology)
were not included (n  3682).
CRN uses a condensed staging system for lung cancer
reporting, based on the TNM classification system, in that
T1-2N0M0 is “Localized,” M1 is “Metastatic,” and the others
are “Regionally advanced.” Tumor localization was through
1992 coded according to ICD-7, and tumor histology was
coded according to Manual of Tumor Nomenclature and
Coding (1968).10 Since 1993, both topography and morphol-
ogy have been coded according to ICD-O.11 A standardized
national treatment protocol for the treatment of lung cancer
was implemented in 2000. We collected data from 1988,
since after that time point, computerized tomography was in
widespread use, implying that diagnosis and staging should
be uniform throughout the country.
RESULTS
Patient Characteristics
A total of 40,118 cases were included in the study, in
which 6,597 cases (16.4%) were carcinomas NOS; 4,284
(65%) men and 2,313 (35%) women. Clinicopathological
characteristics for all patients are reported in supplementary
Table 1 (http://links.lww.com/JTO/A156) and for carcinoma
NOS patients in Table 1.
Age-Specific Incidence and Survival
Among all 40,118 patients, annual average rates in
age-specific incidence in males increased slightly (1.6%) in
the age group 70 to 79 years and more notably (4.4%) in the
age group 80 years and older (Figure 1A) in the period 1988
to 2007. The proportion of patients in this age group (80)
increased from 11% in 1988 to 19% in 2007 (Figure 1B). In
women, age-specific IRs increased in all age groups, 50 years
and older, and were most pronounced in those aged 60 years
and older, which recorded average annual increases from
4.2% to 5.3% (Figure 1C). Similar to what was observed in
men, the largest increase in proportion of cases was seen in
TABLE 1. Carcinoma NOS Patient Characteristics Stratified by Diagnostic Period and Sex
1988–1992 1993–1997 1998–2002 2003–2007 Total (1988–2007)
M F M F M F M F M F
Carcinoma NOS (%) 752 (68) 356 (32) 1035 (67) 507 (33) 1096 (64) 617 (36) 1401 (63) 833 (37) 4284 (65) 2313 (35)
5-yr relative survival
(95% CI)
3.8 (2.4–5.9) 5.9 (3.5–9.2) 5.4 (3.9–7.2) 7.4 (5.1–10.3) 3.8 (2.6–5.3) 5.7 (3.9–8) 7.1 (4.9–9.9) 7.8 (5.3–11) 5.1 (4.2–6) 7.1 (5.9–8.5)
Stage (%)
Localized disease 254 (34) 112 (31) 323 (31) 156 (31) 223 (20) 124 (20) 253 (18) 173 (21) 1053 (25) 565 (24)
Regional disease 350 (47) 180 (51) 486 (47) 253 (50) 593 (54) 349 (57) 710 (51) 439 (53) 2139 (50) 1221 (53)
Metastatic disease 129 (17) 60 (17) 212 (20) 87 (17) 268 (24) 142 (23) 424 (30) 208 (25) 1033 (24) 497 (21)
Unknown 19 (3) 4 (1) 14 (1) 11 (2) 12 (1) 2 (0) 14 (1) 13 (2) 59 (1) 30 (1)
Age (%)
0–49 yr 36 (5) 21 (6) 50 (5) 46 (9) 40 (4) 46 (7) 36 (3) 36 (4) 162 (4) 149 (6)
50–59 yr 100 (13) 51 (14) 127 (12) 83 (16) 174 (16) 136 (22) 190 (14) 163 (20) 591 (14) 433 (19)
60–69 yr 249 (33) 121 (34) 332 (32) 149 (29) 286 (26) 168 (27) 404 (29) 222 (27) 1271 (30) 660 (29)
70–79 yr 292 (39) 115 (32) 392 (38) 169 (33) 447 (41) 202 (33) 500 (36) 295 (35) 1631 (38) 781 (34)
Aged 80 years and older 75 (10) 48 (13) 134 (13) 60 (12) 149 (14) 65 (11) 271 (19) 117 (14) 629 (15) 290 (13)
Diagnostic methods (%)
Biopsy metastasis 88 (15) 52 (12) 153 (15) 68 (13) 146 (13) 89 (14) 156 (11) 106 (13) 543 (13) 315 (14)
Biopsy primary tumor 501 (67) 238 (67) 670 (65) 333 (66) 635 (58) 344 (56) 883 (63) 518 (62) 2689 (63) 1433 (62)
Cytology 163 (19) 66 (22) 212 (20) 106 (21) 315 (29) 184 (30) 362 (26) 209 (25) 1052 (25) 565 (24)
M, male; F, female; NOS, not otherwise specified; CI, confidence interval.
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those 80 years and older, comprising 14% in 1988 and 18%
in 2007 (Figure 1D). Among carcinoma NOS patients, 47%
of women and 53% of men were 70 years and older (Table 1).
Compared with the youngest age group (0–49 years), pa-
tients 80 years and older were at 21% increased risk of death
within 5 years of diagnosis when adjusted for covariates
(Table 2, Figure 2A).
Carcinomas NOS
Within the 20-year period studied, the proportion of
carcinomas NOS increased from 12% in 1988 to 19% in
2007. The proportion of carcinoma NOS patients diagnosed
with localized disease was smaller than in the group overall
(Table 1, Supplementary Table 1), and crude 5-year RS in
carcinoma NOS was lowest of all NSCLC entities throughout
the 20-year period studied (Supplementary Table 2). Ad-
justed for covariates carcinoma NOS-patients had poor sur-
vival compared with other histological subgroups, with a
20% increased risk of death (hazard ratio [HR]  1.20; 95%
confidence interval [CI]  1.16–1.24) within 5 years of
diagnosis compared with adenocarcinoma patients (Table
2). Men diagnosed with carcinoma NOS in the period 2003
to 2007 had a 12% increased risk of dying within 5 years
of diagnosis compared with women (HR  1.12; 95%
CI  1.07–1.16; Table 2, Figure 2B). Furthermore, pa-
tients diagnosed with carcinoma NOS in the period 2003 to
2007 had about 16% lower risk of dying compared with
patients diagnosed between 1988 and 1992 (HR  0.84;
95% CI, 0.79–0.90; Table 2).
Diagnostic Methods
Among all histological subgroups, 25% of all cases
diagnosed by cytology were carcinomas NOS in 1988 to
1992. By the last 5-year period studied (2003–2007), this
number had increased to 38%, making it the histological
entity most commonly diagnosed by cytology (data not
shown). Nevertheless, when looking at the distribution of
diagnostic methods among carcinomas NOS only, the pro-
portion of carcinomas NOS diagnosed by cytology increased
slightly during the last 20 years, and more notably so in men
(from 19 to 25%; Table 1). Most lung cancers are still
diagnosed by biopsy of the primary lesion, although the
proportion is lower among carcinomas NOS than among
other histological entities (e.g., 62% of all carcinomas NOS
versus 84% of all squamous cell carcinomas; Table 3). Older
age was associated with an increasing use of cytology, and
17% of all patients aged 80 years and older were diagnosed
by this method versus 11% of those aged 60 to 69 years
(Table 3, Figure 3). Moreover, among patients diagnosed
with radiological methods (cases of unknown histology), the
largest proportion of cases were 80 years and older (24%;
Table 3, Figure 3).
FIGURE 1. A, Age-specific lung cancer incidence in men (all histological subgroups), (B) age distribution in men with lung
cancer, (C) age-specific lung cancer incidence in women, and (D) age distribution in women with lung cancer.
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DISCUSSION
Recent changes in diagnostic demands related to new
treatment regimens that require a differentiation between
histological subsets of NSCLC have led to increased attention
on the large proportion of carcinomas NOS reported from
several cancer registry databases.12,13 It is important, when
interpreting epidemiological trends, to have access to reliable
supplemental clinical data as a changing patient demographic
influence choice of diagnostic methods, treatment, and prog-
nosis. Our database encompass 40,000 lung cancer cases,
including 6,000 patients with a histopathological diagnosis
of carcinoma NOS. We assessed how the epidemiological
features of this histological entity coincide with an aging
patient population and diagnostic methods used.
Our study illustrates several important characteristics of
the lung cancer epidemic. The proportion of elderly patients
(70 years and older) have currently increased to over half of
all patients diagnosed. Furthermore, although the use of
diagnostic methods among separate histological entities have
not varied significantly throughout the years, we observed an
increased proportion and a doubling of the number of carci-
nomas NOS cases reported to the cancer registry in this
20-year period.
Age-Specific Incidence and Survival
In our material, age-specific IRs increased most among
patients 70 years and older. Not surprisingly, increased life
expectancy reflects an epidemiological transition in the lead-
ing causes of death in developed nations that is also seen in
other databases, and the aging patient population trend is in
agreement with a recent Surveillance, Epidemiology and End
Results database analysis.2 As found elsewhere,13 the largest
proportion of carcinomas NOS also occurred in those 70
years and older, hence an increase in the proportion of
carcinomas NOS could be attributed to the population aging.
Nevertheless, we have previously observed an increase in the
age-adjusted IR of carcinoma NOS, irrespective of a chang-
ing age distribution.1
We must assume that old age is associated with a higher
number of comorbidities that affect therapeutic options and
prognosis,14 although such data are not collected in the cancer
registry database. Despite our observation that increasing age
is associated with decreasing 5-year RS, age alone should not
preclude diligent diagnostic workup, as exemplified by favor-
able long-time survival rates in elderly operated lung cancer
patients.3,15
Age and Diagnostic Methods
We found that the use of different diagnostic proce-
dures varied greatly depending on the age of the patient. With
more recent development of safer and less invasive methods
of diagnosis, one could expect an increasing number of
microscopically verified tumors in older age groups. Yet our
results show the opposite; the age group 80 years and older
had the largest proportion of cases diagnosed by radiology
throughout this 20-year period, with no signs of a decrease. In
more recent years, there has been greater focus on the
development of clinical trials that specifically address lung
cancer treatment in the elderly, and it has now become clear
that many elderly patients can tolerate and benefit from
standard treatments for lung cancer. A less frequent use of
invasive diagnostics methods in elderly will inadvertedly
limit the accuracy of a histopathological diagnosis and there-
fore restrict treatment options.
Carcinoma NOS
The proportion of carcinoma NOS cases has increased
over the last 20 years and currently comprises 19% and 17%
of all lung cancer cases in men and women, respectively. A
large or growing proportion of carcinoma NOS have also
been reported in other cancer registry databases,12,13 and in a
retrospective, population-based study of NSCLC patients
diagnosed either by histology or cytology from the California
Cancer Registry, carcinoma NOS accounted for 22% of all
NSCLC cases.
When assessing trends in histology distribution, histo-
logical classification of lung cancer should ideally be based
on differentiation of the whole tumor in accordance with the
TABLE 2. Cox Proportional Hazards Model Fitted to Estimate
the Relative Risk of Death for Males versus Females with
Carcinoma NOS and Adjusted for the Covariates Stage, Age,
and Diagnostic Period in Addition to Survival by Histology
Hazard Ratio
(95% CI) p
Gender (adjusted for stage, age
and period of diagnosis)
Femalea
Male 1.116 (1.069–1.164) 0.001
Stage (adjusted for age and period
of diagnosis)
Localized diseasea
Regional disease 1.331 (1.235–1.434) 0.001
Metastatic disease 2.365 (2.213–2.527) 0.001
Unknown stage 1.879 (1.750–2.018) 0.001
Age (yr) (adjusted for stage and
period of diagnosis)
0–49a
50–59 1.116 (0.980–1.271) 0.099
60–69 1.312 (1.161–1.482) 0.001
70–79 1.645 (1.460–1.854) 0.001
Aged 80 years and older 2.093 (1.852–2.366) 0.001
Period of diagnosis (adjusted for
stage and age)
1988–1992a
1993–1997 0.974 (0.914–1.038) 0.426
1998–2002 0.936 (0.880–0.996) 0.038
2003–2007 0.844 (0.794–0.897) 0.001
Histology (adjusted for stage, age
and period of diagnosis)
Adenocarcinomaa
NOS 1.198 (1.156–1.241) 0.001
Squamous cell carcinoma 0.976 (0.945–1.009) 0.150
Small cell carcinoma 1.170 (1.132–1.210) 0.001
Large cell carcinoma 1.122 (1.062–1.185) 0.001
a Reference group.
NOS, not otherwise specified; CI, confidence interval.
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World Health Classification (WHO) classification.16 Surgical
samples are bigger, hence reduce the obstacle of tumor
heterogeneity17 and chance of possible interobserver variabil-
ity compared with small biopsies.18 Nevertheless, with cur-
rent national surgery rates, only 22% of patients will have
their initial diagnosis confirmed by surgery. According to the
2004 WHO classification of lung cancer, large-cell carcinoma
can only be accurately classified on surgical material, and it
has previously been recommended that the classification
NSCLC NOS is used instead in small biopsy specimens.19,20
We found the proportion of large-cell carcinoma decreased
during these 20 years, possibly at the expense of an increas-
ing number of carcinomas NOS, as more pathologists follow
these diagnostic guidelines.
It is unlikely that regional changes in evaluation of
diagnostic material have had an impact in the increased
proportion of carcinoma NOS cases seen. Traditionally, the
initial diagnosis of lung cancer patients in Norway is carried
out by local hospitals. Local pathology reports are only
verified by pathologist at major regional hospitals before
planned surgery. Surgical treatment of lung cancer has be-
come more centralized in recent years, and histological diag-
nosis is therefore more often verified both at local and
regional hospitals. One could therefore expect, contrary to
our results, a decrease in the proportion of carcinoma NOS if
this diagnosis was associated with the diagnostic experience
linked to regional diagnostic centers.
Changes in diagnostic techniques might have had an
impact on the increased proportion of carcinomas NOS ob-
served. Although the proportion of carcinomas NOS diag-
nosed by cytology versus biopsy was largely unchanged
throughout the 20-year period studied, specification of diag-
nostic tools (e.g., sputum cytology, bronchoscopy, and trans-
thoracic needle aspirate) was not registered in our database
but clustered under the diagnostic headings “cytology” or
“biopsy.” Diagnostic accuracy can vary with diagnostic tech-
niques; one study suggested lower diagnostic accuracy with
transthoracic needle biopsy compared with bronchial bi-
opsy.21 Nevertheless, a study by Gong et al.22 showed a
comparable diagnostic accuracy of fine needle aspiration
(85.1%) and core needle biopsy (86.7%) for malignant in-
trathoracic tumors and for histological typing (86.4 versus
85.2%). Another recent study by Sackett et al.23 have shown
there is little discordance in differentiating NSCLC from
SCLC in cytology versus biopsy samples. Cytology and
biopsy specimens also seem to have similar cell-typing ac-
curacy, although diagnostic yield is not always good
FIGURE 2. (A) Survival in carcinoma NOS patients stratified by age group and adjusted for stage and diagnostic period. (B)
Survival in carcinoma NOS patients stratified by sex and adjusted for stage, age, and diagnostic period.
TABLE 3. Distribution of Diagnostic Methods Used among






Adenocarcinoma (%) 1310 (12) 7843 (75) 1421 (13)
Squamous cell carcinoma 393 (4) 7909 (85) 1061 (11)
Carcinoma NOS 858 (13) 4122 (62) 1617 (25)
Small-cell carcinoma 1211 (17) 5296 (73) 744 (10)
Large-cell carcinoma 260 (14) 1444 (77) 159 (9)
Age (yr)
0–49 299 (14.6) 1576 (77.2) 135 (6.6)
50–59 857 (14.1) 4484 (73.7) 613 (10.1)
60–69 1355 (11.4) 8727 (73.5) 1297 (10.9)
70–79 1311 (9.1) 9791 (68) 1987 (13.8)
Aged 80 years and older 345 (6.0) 2637 (46.1) 979 (17.1)
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enough.24,25 We, therefore, cannot conclude, despite just a
small shift in the distribution of diagnostic approaches, if
changes in diagnostic techniques that register under the main
diagnostic headings biopsy and cytology have had an impact
in the increased proportion of carcinomas NOS observed.
A greater proportion of patients with carcinomas NOS
were diagnosed at a later stage of the disease than we
observed in the group overall. This might partly be explained
by the biological aggressiveness of some of the poorly dif-
ferentiated tumors. Although carcinoma NOS patients
showed increasing long-term survival over the course of 20
years, survival is still among the poorest of all histological
entities, only surpassed by small-cell carcinoma, also when
adjusted for covariates including stage.1
The predictive value of histological subclassification of
NSCLC has only become apparent in recent years.6,26,27 More
information is requested from less tissue, yet improvements
in diagnostic accuracy seem possible with changes in pathol-
ogists’ approach to diagnosis28,29; an immunohistochemical
approach to clarify the accurate subtype in undifferentiated
NSCLC cases in small biopsy samples may improve the
diagnostic algorithm of NSCLC.17 Still, the advent of molec-
ular targeted therapies raises questions how to treat the
current large number of carcinomas NOS. The Eastern Co-
operative Oncology Group E4599 study, that showed a sur-
vival benefit when adding bevacizumab to a standard, platin-
based, two-agent regiment in patients with metastatic
NSCLC, included 19% of patients with carcinoma NOS.6
Nevertheless, a later analysis stratified by histology to assess
if prognosis differed between adenocarcinoma and carcinoma
NOS showed no significant survival benefit in carcinoma
NOS patients with the addition of bevacizumab.30
In conclusion, although it may seem like we are on the
verge of a paradigm shift in treatment, and hopefully out-
come, of lung cancer with the emergence of molecular tar-
geted and histology-specific therapies, our report conveys
important trends in patient demographics that limit use of
new treatment options. The increasing proportion of elderly
lung cancer patients represents challenges for the clinician,
both in diligence of diagnostic workup and in choosing
optimal treatment regimens. A further focus on clinical trials
designed to address this trend is therefore warranted. The
increasing proportion of carcinomas NOS might be attributed
to several factors, but is none the less an unfortunate
development in light of increasing use of subtype-specific
treatment regimens. Less invasive diagnostic procedures
come at a cost of smaller tissue samples. Sparseness of
excess tissue might halter implementation of molecular
profiling, a field of great future promise, both for research
and routine diagnostics.
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